PMID- 33841138
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240331
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With 
      Cancer: A National Cross-Sectional Survey.
PG  - 583126
LID - 10.3389/fphar.2021.583126 [doi]
LID - 583126
AB  - Immune-checkpoint inhibitors (ICIs) are revolutionizing the field of 
      immuno-oncology. Side effects and tumor microenvironment currently represent the 
      most significant obstacles to using ICIs. In this study, we conducted an 
      extensive cross-sectional survey to investigate the concept and practices 
      regarding the use of ICIs in cancer patients in China. The results provide 
      real-world data on the adverse events (AEs) of ICIs and the factors influencing 
      the use of ICIs. This survey was developed by the Expert Committee on 
      Immuno-Oncology of the Chinese Society of Clinical Oncology (CSCO-IO) and the 
      Expert Committee on Patient Education of the Chinese Society of Clinical Oncology 
      (CSCO-PE). The surveys were distributed using a web-based platform between 
      November 29, 2019 and December 21, 2019. A total of 1,575 patients were included. 
      High costs (43.9%), uncertainty about drug efficacy (41.2%), and no reimbursement 
      from medical insurance (32.4%) were the factors that prevented the patients from 
      using ICIs. The patients were most concerned about the onset time or effective 
      duration of ICIs (40.3%), followed by the indications of ICIs and pre-use 
      evaluation (33.4%). Moreover, 9.0, 57.1, 21.0, and 12.9% of the patients reported 
      tumor disappearance, tumor volume reduction, no change in tumor volume, and 
      increased tumor volume. Among the patients who received ICIs, 65.7% reported 
      immune-related AEs (irAEs); 96.1% reported mild-to-moderate irAEs. Cancer 
      patients in China had a preliminary understanding of ICIs. Yet, the number of 
      patients treated with ICIs was small.
CI  - Copyright (c) 2021 Zhang, Wang, Zhang, Chu, Su, Wu, Chen, Wang, Yin, Zhu and Sun.
FAU - Zhang, Luping
AU  - Zhang L
AD  - Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Oncology, The First Affiliated Hospital of Shandong First Medical 
      University, Jinan, China.
FAU - Zhang, Bicheng
AU  - Zhang B
AD  - Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Chu, Qian
AU  - Chu Q
AD  - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Su, Chunxia
AU  - Su C
AD  - Associate Chief Physician of Medical Oncology, Shanghai Pulmonary Hospital and 
      Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
FAU - Wu, Hao
AU  - Wu H
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Chen, Xiaobing
AU  - Chen X
AD  - Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 
      Henan Cancer Hospital, Zhengzhou, China.
FAU - Wang, Baocheng
AU  - Wang B
AD  - Department of Oncology, No. 960 Hospital of PLA, Jinan, China.
FAU - Yin, Yongmei
AU  - Yin Y
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Zhu, Bo
AU  - Zhu B
AD  - Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China.
FAU - Sun, Jianguo
AU  - Sun J
AD  - Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China.
LA  - eng
PT  - Journal Article
DEP - 20210322
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8025873
OTO - NOTNLM
OT  - adverse effects
OT  - attitude
OT  - immunotherapy
OT  - practice
OT  - survey
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/04/13 06:00
MHDA- 2021/04/13 06:01
PMCR- 2021/03/22
CRDT- 2021/04/12 06:16
PHST- 2020/07/17 00:00 [received]
PHST- 2021/01/26 00:00 [accepted]
PHST- 2021/04/12 06:16 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/04/13 06:01 [medline]
PHST- 2021/03/22 00:00 [pmc-release]
AID - 583126 [pii]
AID - 10.3389/fphar.2021.583126 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Mar 22;12:583126. doi: 10.3389/fphar.2021.583126. 
      eCollection 2021.